ISRCTN90482012 https://doi.org/10.1186/ISRCTN90482012

Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Submission date 14/08/2024	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 03/09/2024	**Overall study status** Deferred	
Last Edited 16/05/2025	**Condition category** Other	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Prof Kyriakos Lobotesis

ORCID ID
https://orcid.org/0000-0001-5093-9751

Contact details
Imperial College Healthcare NHS Trust
Charing Cross Hospital
Fulham Palace Road
London
United Kingdom
W6 8RF
-
k.lobotesis@nhs.net

Type(s)
Public, Scientific

Contact name
Dr Philip Pratt

Contact details
Medical iSight (UK) Ltd
9th Floor
107 Cheapside
London
United Kingdom
EC2V 6DN
-
pjp@medicalisight.com

Additional identifiers

Integrated Research Application System (IRAS)
319189

Central Portfolio Management System (CPMS)
54208

Study information

Scientific Title
Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Acronym
MAROG-INR

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
approved 21/02/2023, London - Dulwich Research Ethics Committee (Skipton House, 80 London Road, London, SE1 6LH, United Kingdom; +44 (0)207 104 8290; dulwich.rec@hra.nhs.uk), ref: 23/LO/0030

Study design
Single-centre interventional trial in patients undergoing interventional neuroradiology procedures

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Other

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s))
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
01/07/2026

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

01/09/2024

Date of final enrolment
01/04/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Charing Cross Hospital
Fulham Palace Road
London
United Kingdom
W6 8RF

Sponsor information

Organisation
Medical iSight (UK) Limited

Funder(s)

Funder type
Other

Funder Name
Self-funded

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available